期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 68, 期 -, 页码 372-384出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2013.07.037
关键词
SARS; SARS-CoV 3CL(Pro); Dipeptide; Peptidomimetics; Cysteine protease inhibitors
资金
- Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [23.01104, 23659059]
- National Institutes of Health [GM57144, GM56550]
- National Science Foundation [MCB-1157506]
- Grants-in-Aid for Scientific Research [23659059, 25460160] Funding Source: KAKEN
- Direct For Biological Sciences
- Div Of Molecular and Cellular Bioscience [1157506] Funding Source: National Science Foundation
We report the design and synthesis of a series of dipeptide-type inhibitors with novel P3 scaffolds that display potent inhibitory activity against SARS-CoV 3CL(Pro). A docking study involving binding between the dipeptidic lead compound 4 and 3CL(pro) suggested the modification of a structurally flexible P3 N-(3-methoxyphenyl)glycine with various rigid P3 moieties in 4. The modifications led to the identification of several potent derivatives, including 5c-k and 5n with the inhibitory activities (K-i or IC50) in the sub-micromolar to nanomolar range. Compound 5h, in particular, displayed the most potent inhibitory activity, with a K-i value of 0.006 mu M. This potency was 65-fold higher than the potency of the lead compound 4 (K-i = 0.39 mu M). In addition, the K-i value of 5h was in very good agreement with the binding affinity (16 nM) observed in isothermal titration calorimetry (ITC). A SAR study around the P3 group in the lead 4 led to the identification of a rigid indole-2-carbonyl unit as one of the best P3 moieties (5c). Further optimization showed that a methoxy substitution at the 4-position on the indole unit was highly favorable for enhancing the inhibitory potency. (C) 2013 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据